Solid Biosciences Inc (SLDB) - News Archive

Understanding the Implications of Solid Biosciences Inducement GrantsIn a recent announcement that could signal a new chapter for Solid Biosciences Inc. (Nasdaq: SLDB), the company disclosed grants of 81,000 restricted...

Solid Biosciences: Navigating Financial Headwinds with Strategic Inducements in Gene TherapyIn a dynamic world of biotechnology where each step forward holds the potential for groundbreaking advancements, Solid Bioscien...

Outlining the Facts:1. Underwritten Offering: - Solid Biosciences Inc. priced an underwritten offering of 35,739,810 shares at $4.03 per share and pre-funded warrants for 13,888,340 shares at $4.029 each. - The total gr...

Solid Biosciences Inc. a trailblazer in the field of precision genetic therapies, has recently garnered attention with the FDA’s Fast Track designation for its dual-route gene therapy, SGT-212, aimed at treating Friedre...

Advancements in Neuromuscular and Cardiac Development: Solid Biosciences Precision Genetic Medicine Initiatives Solid Biosciences Inc. a key player in the development of treatments for neuromuscular and cardiac conditio...

: In a significant advancement for the treatment of Friedreich s ataxia (FA), Solid Biosciences has announced the U.S. Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application for SG...

Solid Biosciences: A New Dawn with Nasdaq Biotechnology Index Inclusion Amid Financial ChallengesCharlestown, Mass. On December 23, 2024, Solid Biosciences Inc. (Nasdaq: SLDB) made a significant stride in its corporate...

Charlestown, Mass. November 4, 2024 Solid Biosciences Inc. (Nasdaq: SLDB), a pioneering life sciences company specializing in precision genetic medicines for neuromuscular and cardiac diseases, has once again demonstrat...

Solid Biosciences Announces Stock Inducement Grants Amidst Rising Share ValueCHARLESTOWN, Mass. In a strategic move to attract and retain top talent, Solid Biosciences Inc. (Nasdaq: SLDB), a pioneering life sciences ent...

CHARLESTOWN, Mass. Sept. 04, 2024 - Solid Biosciences Inc. (Nasdaq: SLDB), a distinguished life sciences company focused on developing precise genetic medicines to combat neuromuscular and cardiac diseases, has recently...

Solid Biosciences Inc., a leading life sciences company specializing in the development of precision genetic medicines for neuromuscular and cardiac diseases, has recently announced the issuance of 11,847 restricted sto...

Solid Biosciences Inc. (Nasdaq: SLDB), a prominent life sciences company dedicated to the development of precision genetic medicines for neuromuscular and cardiac diseases, recently made a significant announcement. On J...

Solid Biosciences Grants Inducement Awards to Newly Hired Employees, Share Price Dips in Q2 2024CHARLESTOWN, Mass., April 03, 2024 - Solid Biosciences Inc. (Nasdaq: SLDB), a leading life sciences company focusing on pre...

FDA s green flagging of SGT-003 complements Solid Biosciences previous success, as the gene therapy candidate has already been granted Orphan Drug and Fast Track Designations within the U.S.. Rare Pediatric Disease Desi...

Enhancing the Development of RNAi Therapy for FSHD: Solid Biosciences Announces Licensing Agreement with Armatus BioIn a significant stride towards advancing RNA interference (RNAi) therapy for the treatment of Faciosca...

Solid Biosciences Announces Groundbreaking $109 Million Private Placement for Advancing Precision Genetic MedicinesCharlestown, Mass., Jan. 08, 2024 - Solid Biosciences Inc. (Nasdaq: SLDB), a cutting-edge life sciences...